BetaEntity Annotation Prototype
← Back to institutions

Annotated abstract

Statin labelling may overstate adverse events

dtb · 2026-04-29 · canonical JSON source

2 visible annotations · policy: published · automated confidence ≥ 75.00%

Document resource

Abstract Overview of: Cholesterol Treatment Trialists’ (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet 2026;407(10529):689-703.